SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 58 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $77,000 | -29.4% | 14,200 | -2.7% | 0.00% | -33.3% |
| Q1 2021 | $109,000 | -29.2% | 14,600 | +2.8% | 0.00% | -25.0% |
| Q4 2020 | $154,000 | +20.3% | 14,200 | -2.1% | 0.00% | -33.3% |
| Q3 2020 | $128,000 | -15.2% | 14,500 | +2.1% | 0.01% | -25.0% |
| Q2 2020 | $151,000 | +1272.7% | 14,200 | +1094.3% | 0.01% | +700.0% |
| Q2 2019 | $11,000 | +37.5% | 1,189 | +58.5% | 0.00% | 0.0% |
| Q2 2018 | $8,000 | +60.0% | 750 | +53.1% | 0.00% | – |
| Q4 2017 | $5,000 | -54.5% | 490 | -34.7% | 0.00% | -100.0% |
| Q3 2017 | $11,000 | -42.1% | 750 | -37.8% | 0.00% | -50.0% |
| Q2 2017 | $19,000 | – | 1,205 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures Fund IV General Partner LLC | 4,806,656 | $87,241,000 | 14.92% |
| Aisling Capital LLC | 908,565 | $16,490,000 | 3.89% |
| Foresite Capital Management III, LLC | 150,000 | $2,723,000 | 1.87% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,095,220 | $38,028,000 | 1.50% |
| Redmile Group, LLC | 946,182 | $15,058,000 | 1.44% |
| Casdin Capital, LLC | 50,000 | $908,000 | 0.90% |
| Eventide Asset Management | 150,000 | $2,723,000 | 0.17% |
| Weiss Multi-Strategy Advisers LLC | 45,857 | $832,000 | 0.06% |
| Baker Brothers Advisors | 204,465 | $3,711,000 | 0.04% |
| Alyeska Investment Group, L.P. | 70,000 | $1,271,000 | 0.01% |